- Home
- NAAS vs NRSN Comparison
NAAS vs NRSN Comparison
Compare NAAS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- NRSN
- Stock Information
- Founded
- NAAS 2019
- NRSN 2017
- Country
- NAAS China
- NRSN Israel
- Employees
- NAAS N/A
- NRSN N/A
- Industry
- NAAS Other Specialty Stores
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- NRSN Health Care
- Exchange
- NAAS Nasdaq
- NRSN Nasdaq
- Market Cap
- NAAS 18.9M
- NRSN 17.8M
- IPO Year
- NAAS 2017
- NRSN 2021
- Fundamental
- Price
- NAAS $1.63
- NRSN $1.09
- Analyst Decision
- NAAS
- NRSN Hold
- Analyst Count
- NAAS 0
- NRSN 1
- Target Price
- NAAS N/A
- NRSN N/A
- AVG Volume (30 Days)
- NAAS 4.4M
- NRSN 159.3K
- Earning Date
- NAAS 03-27-2025
- NRSN 04-04-2025
- Dividend Yield
- NAAS N/A
- NRSN N/A
- EPS Growth
- NAAS N/A
- NRSN N/A
- EPS
- NAAS N/A
- NRSN N/A
- Revenue
- NAAS $43,258,393.00
- NRSN N/A
- Revenue This Year
- NAAS $19.53
- NRSN N/A
- Revenue Next Year
- NAAS $151.36
- NRSN N/A
- P/E Ratio
- NAAS N/A
- NRSN N/A
- Revenue Growth
- NAAS 50.34
- NRSN N/A
- 52 Week Low
- NAAS $1.30
- NRSN $0.51
- 52 Week High
- NAAS $34.20
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- NAAS 51.51
- NRSN 44.12
- Support Level
- NAAS $1.32
- NRSN $1.12
- Resistance Level
- NAAS $1.95
- NRSN $1.24
- Average True Range (ATR)
- NAAS 0.24
- NRSN 0.08
- MACD
- NAAS 0.03
- NRSN -0.01
- Stochastic Oscillator
- NAAS 27.05
- NRSN 13.57
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.